An Expanding Product Portfolio
Impax’s ongoing strategy to invest in R&D to develop high-value opportunities should continue to provide the potential for growth in the future.
We currently manufacture and market 133 generic pharmaceutical products, which represent dosage variations of 39 different pharmaceutical compounds through our Global Pharmaceuticals division; another 14 of our generic pharmaceutical products representing dosage variations of four different pharmaceutical compounds are marketed by our alliance agreement partners. A list of our currently marketed generic products can be found here.
Impax Pharmaceuticals, our branded division, is currently promoting Zomig® nasal spray in the United States.
We currently have 44 pending Abbreviated New Drug Applications (ANDA) at the FDA. We are also working on an additional 25 products under development with many having the potential to be first-to-file or first-to-market opportunities.
Within our branded division we are currently developing:
- One late-stage branded pharmaceutical product candidate which we are developing internally, RYTARY™ (IPX066), an extended release capsule formulation of carbidopa-levodopa for the treatment of symptomatic Parkinson’s disease, for which an NDA was accepted for filing by the FDA in February 2012. In January 2013, the FDA issued a Complete Response Letter regarding the NDA for RYTARY™. We are working with the FDA on the appropriate next steps for the RYTARY™ NDA.
- The Company currently has four additional neurology products in various stages of development and review by its R&D team.